Ligand PharmaceuticalsLGND
Market Cap: $1.92B
About: Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Employees: 58
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
848% more call options, than puts
Call options by funds: $6.3M | Put options by funds: $665K
100% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 4 (+2) [Q2]
45% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 29
20% more capital invested
Capital invested by funds: $1.22B [Q1] → $1.45B (+$238M) [Q2]
14% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 72
6% more funds holding
Funds holding: 219 [Q1] → 232 (+13) [Q2]
2.01% more ownership
Funds ownership: 94.04% [Q1] → 96.05% (+2.01%) [Q2]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
Benchmark Robert Wasserman 62% 1-year accuracy 21 / 34 met price target | 5%upside $110 | Buy Maintained | 12 Aug 2024 |
RBC Capital Douglas Miehm 0 / 0 met price target | 24%upside $130 | Outperform Reiterated | 12 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 42% 1-year accuracy 42 / 99 met price target | 37%upside $144 | Buy Reiterated | 8 Aug 2024 |
RBC Capital Douglas Miehm 0 / 0 met price target | 24%upside $130 | Outperform Reiterated | 7 Aug 2024 |
RBC Capital Douglas Miehm 0 / 0 met price target | 24%upside $130 | Outperform Initiated | 30 Jul 2024 |
Financial journalist opinion
Based on 3 articles about LGND published over the past 30 days